Letters: New Observations
Dysregulation of novel catecholamine-regulated protein 40 (CRP40) in Parkinson's disease patients
Funding agencies: This work was funded by the Quebec Consortium for Drug Discovery and by the Canadian Institute of Health Research.
Relevant conflicts of interest/financial disclosures: Joseph P. Gabriele and Ram K. Mishra jointly hold a patent on Mortalin and its alternative gene product, CRP40.
Full financial disclosures and author roles may be found in the online version of this article.
No abstract is available for this article.